Table 3.

Significance^* of patient-reported outcomes reduction during the six months post-SBRT

	MDASI symptom models†					MDASI symptom interference model	HRQOL models (SF-12 component scores)
Variable	Pain	Fatigue	Distress	Disturbed sleep	Drowsiness	Composite interference Score	Physical	Mental health
Weeks of treatment	0·00003‡	0·03651	0·00493‡	0·00008‡	0·00005‡	0·0066‡	0·28	0·47
Age	0·59	0·85	0·36	0·06	0·28	0·47	0·16	0·98
Sex (female vs. male)	0·00214	0·00298	0·00461	0·02484	0·03328	0·07	0·12	0·0347
Metastatic tumor volume	0·78	0·71	0·30	0·93	0·91	0·40	0·97	0·98
Diagnosis (lung vs. renal)	0·97	0·20	0·15	0·56	0·25	0·16	0·25	0·58
Progression status at six months (failure vs. no failure)	<0·0001‡	0·0104	0·05	0·09	0·00008‡	0·0022‡	0·0001‡	0·65
Opioids use during six months	<0·0001‡	<0·0001‡	0·0004‡	0·00364‡	0·0004‡	0·0001‡	<0·0001‡	0·06
Baseline Karnofsky performance status	0·72	0·08	0·0073	0·67	0·29	0·0003‡	0·0002‡	0·033

SBRT=stereotactic body radiotherapy. MDASI =M. D. Anderson Symptom Inventory. HRQOL= health related quality of life.

^*Significance testing was performed by mixed-effect regression analysis. Results in this table are the p-values.

^†MDASI symptom models: each symptom as an individual model. Symptom outcome was measure by M. D. Anderson Symptom Inventory.

^‡Significant at p<0·00625, after adjusting for multiple comparisons (8 models).